Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04040205 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
A Phase 2 study of Soft Tissue Sarcoma and Osteosarcoma, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 4
- Study locations
NCT04040205 is a Phase 2 study of Soft Tissue Sarcoma and Osteosarcoma that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 44 participants, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (44% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04040205, a Phase 2 study of Soft Tissue Sarcoma and Osteosarcoma, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a single-arm, phase II study that will enroll a total of 45 subjects. All subjects will have a confirmed diagnosis of metastatic or unresectable soft tissue sarcoma or bone sarcoma. All subjects must have intact Rb, identified at the time of screening, by immunohistochemistry testing of submitted tumor specimen. Subjects will receive Abemaciclib 200 mg twice daily until progression or discontinuation criteria are met.
Conditions Studied
Interventions
- DRUG Abemaciclib
Study Locations (4)
Florida
- Mayo Clinic - Jacksonville
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Missouri
- Washington University in St. Louis - St Louis
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2019-10-07 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04040205
The ClinicalTrials.gov registry entry for NCT04040205 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (44% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Abemaciclib is the first listed.
NCT04040205 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Iowa, Missouri.
Frequently Asked Questions
What is clinical trial NCT04040205 about?
NCT04040205 is a clinical study titled "Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration". This is a single-arm, phase II study that will enroll a total of 45 subjects. All subjects will have a confirmed diagnosis of metastatic or unresectable soft tissue sarcoma or bone sarcoma. All subjects must have intact Rb, identified at the time of screening, by immunohistochemistry testing of subm...
What is the current status of trial NCT04040205?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2019-10-07. Estimated completion is 2027-06-01.
What conditions does trial NCT04040205 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma, Osteosarcoma, Chondrosarcoma.
What interventions are being tested in trial NCT04040205?
The interventions under investigation include: Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT04040205?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04040205 being conducted?
This trial has 4 study locations across Florida, Iowa, Missouri, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
RECRUITING · Phase 2
-
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
RECRUITING · Phase 2
-
5-Day Preoperative Radiation for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.